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ABSTRACT
Objectives: To assess the role of nephrectomy as a
risk factor for the development of hypertension and
microalbuminuria.
Design: Prospective, long-term follow-up study.
Setting: Swiss Organ Living-Donor Health Registry.
Participants: All living kidney donors in Switzerland
between 1993 and 2009.
Interventions: Data on health status and renal
function before 1 year and biennially after donation
were collected.
Primary and secondary outcome measures:
Comparison of 1-year and 5-year occurrences of
hypertension among normotensive donors with 1-year
and 5-year estimates from the Framingham
hypertension risk score. Multivariate random intercept
models were used to investigate changes of albumin
excretion after donation, correcting for repeated
measurements and cofactors such as age, male gender
and body mass index.
Results: A total of 1214 donors contributed 3918 data
entries with a completed biennial follow-up rate of 74%
during a 10-year period. Mean (SD) follow-up of donors
was 31.6 months (34.4). Median age at donation was
50.5 years (IQR 42.2–58.8); 806 donors (66.4%) were
women. Donation increased the risk of hypertension after
1 year by 3.64 (95% CI 3.52 to 3.76; p<0.001). Those
participants remaining normotensive 1 year after
donation return to a risk similar to that of the healthy
Framingham population. Microalbuminuria before
donation was dependent on donor age but not on the
presence of hypertension. After nephrectomy,
hypertension became the main driver for changes in
albumin excretion (OR 1.19; 95% CI 0.13 to 2.25;
p=0.03) and donor age had no effect.
Conclusions: Nephrectomy propagates hypertension
and increases susceptibility for the development of
hypertension-induced microalbuminuria.
INTRODUCTION
Knowledge of the health consequences of
living kidney donation, such as the risk of
developing hypertension, may have impor-
tant implication for the long-term medical
follow-up of donors. So far it is uncertain
whether nephrectomy alone is an indepen-
dent risk factor for the development of
hypertension and albuminuria. The occur-
rence of hypertension and albuminuria after
kidney donation has been reported for
decades, but as living organ donations con-
tinue to increase worldwide, the health risks
of donation are viewed more positively.1 2 A
meta-analysis of 48 studies reporting the
outcome of 5145 donors showed a very
minor and clinically non-relevant increased
risk among kidney donors for the develop-
ment of hypertension or proteinuria over
long-term follow-up as compared to age-
matched controls.3 4 However, the quality of
the individual studies was limited by the ret-
rospective study design, extensive loss to
follow-up, small sample size resulting in
underpowered statistical analyses and the
common use of a normal population as
control group, while donors are usually a
Strengths and limitations of this study
▪ The prospective design, the large donor group
and the complete data sets are main assets of
this study.
▪ The study compared the effects with an adequate
control group accounting for the lower cardio-
vascular risk of the donor group.
▪ The study had an excellent overall follow-up rate
of 74%.
▪ Missing information on donors’ smoking habits
and the family history of hypertension, required
assumptions and sensitivity analyses.
▪ The use of antihypertensive medication as a part
of the hypertension definition may lead to an
overstated number of hypertensives.
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positive selection and therefore healthier than the
normal age-matched population.5
Only recently, a new multivariate score based on the
Framingham data to calculate hypertension risks has
become available that allows tackling the problem of
inappropriate comparisons.6 The new score allows
making groups comparable for gender, age, systolic and
diastolic blood pressure, smoking habits and family
history of hypertension. To date, no study, including
among those summarised in the recent meta-analysis,
applied the risk equation in the analysis. Therefore, the
aim of this prospective, long-term follow-up study was to
assess the role of nephrectomy as an independent risk
factor for the development of hypertension and microal-
buminuria in living kidney donors when compared to
estimates from the multivariable hypertension risk score
of the Framingham cohort including all relevant risk
parameters of hypertension for potential donors without
nephrectomy.
METHODS
Written informed consent was obtained from all partici-
pants. The protocol used by the Swiss Organ
Living-Donor Health Registry (SOL-DHR) to collect the
data has been described in detail elsewhere.7 Brieﬂy, all
living kidney donors in Switzerland were enrolled before
donation and followed 1 year after nephrectomy and
biennially thereafter since 1993. Donors’ general practi-
tioners provided medical follow-up data, which were col-
lected by a central registry. So far, there are sequential
data for up to 17 years after donation; the current analy-
sis was restricted to a 10-year follow-up period due to the
scarcity of data beyond this time period. This resulted in
the exclusion of 185 database entries.
Hypertension was deﬁned as blood pressure values
above 140 mm Hg systolic and/or 90 mm Hg diastolic,
or use of any blood pressure-lowering drug. Blood pres-
sure data were reported as a mean of three individual
measurements at each time point taken before and
1 year after donation and thereafter biennially during
life-long follow-up examinations required by the Swiss
transplant law. All new diagnoses of hypertension had to
be veriﬁed by 24 h ambulatory blood pressure recording,
using threshold values of 135/85 mm Hg or higher.
Blood pressure values in the normal range were only
accepted as ‘normal’ if a list of drugs taken the same day
was reported to SOL-DHR to exclude antihypertensive
treatment. Only follow-up examinations with complete
data sets were analysed.
Urine albumin and urine creatinine were measured in
a spot urine sample. A single central laboratory (Viollier
AG, Basel, Switzerland) performed all chemical analysis
in blood and urine. Microalbuminuria was deﬁned as a
ratio of mg albumin to mmol creatinine of 3.3 or more
according to international guidelines.8
For statistical analysis, interval-scaled variates were
summarised with means and SDs or medians and IQRs,
where appropriate. Dichotomous variates were described
as ratios and percentages. To assess the effect of dona-
tion on the occurrence of elevated blood pressure
requiring medication, we ﬁtted the hypertension risk
score of the Framingham cohort6 for 1-year and 4-year
risk of hypertension to our data as follows: for the ﬁrst
year analysis we ﬁtted the data to the distribution prior
to donation after excluding all cases of hypertension
(n=271). For the subsequent 4-year analysis, we focused
on all donors remaining normotensive 1-year after dona-
tion. Since data on smoking habits and family history of
hypertension were not available in our data set, we
created two random variates under the assumption of a
smoking prevalence of 25% using the most recent epide-
miological data of the tobacco monitoring study in
Switzerland9 and took the strength of association from
the hypertension risk score. We assumed positive family
history (both parents) for hypertension of 25% using
data of the Swiss survey on salt intake10 and again took
the strength of association from the hypertension risk
score. We found no Swiss data on the correlation
between the two parameters and therefore assumed no
correlation between smoking habits and positive family
history of hypertension. We performed sensitivity ana-
lyses by repeating the analyses 100 times with each newly
drawn random sample of the two parameters ‘smoking
habits’ and ‘family history of hypertension’ and when
assuming 20% and 30% prevalence rather than 25%.
The estimated probabilities from the Framingham
equations were compared to the probabilities estimated
from two multivariate logistic regression models, using
the occurrence of hypertension 1 or 5 years after dona-
tion as the dependent variate and the available para-
meters of the Framingham equation (age, female
gender, systolic and diastolic blood pressure, body mass
index (BMI), smoking habits, family history of hyperten-
sion and an interaction term of age and diastolic blood
pressure) prior to donation (for the 1-year assessment)
and at 12 months after donation (for the 4-year
assessment).
To examine the parameters associated with microalbu-
minuria prior to donation, a multivariate logistic regres-
sion model was ﬁtted using the following parameters as
dependent variates (hypertension, donor age, male
gender and BMI). To examine the occurrence of micro-
albuminuria in the follow-up, a multivariate random
intercept model with hypertension as an independent
variate and accounting for covariates (donor age, male
gender and BMI) and corrected for repeated measures
per donor, was ﬁtted. This was carried out using the
subject as a random factor. All analyses were performed
using the Stata V.11.2 statistics software package
(StataCorp LP, College Station, Texas, USA).
RESULTS
In the period from April 1993 to December 2009, all
1214 living kidney donors in Switzerland were enrolled
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in the SOL-DHR database, providing 3918 complete
data sets with blood pressure measurements, microalbu-
minuria results and a list of drugs taken the day of blood
pressure measurement. Figure 1 reports the number of
donor follow-up examinations at each time point.
Fifty-nine per cent of donors were related (28% parents,
26% siblings, 5% otherwise), 33% were living partners
and 8% of donors were unrelated to the kidney recipi-
ent. During the 10-year follow-up period, 22 donors died
from non-renal causes, resulting in 61 missed follow-up
examinations. A total of 2704 complete data sets out of
3632 possible follow-up examinations were returned and
analysed by SOL-DHR, resulting in an average follow-up
rate of 74% over all time points. We checked whether
those with hypertension at the 1-year follow-up were
more likely to show up at the 5-year follow-up and found
no signiﬁcant difference (p=0.641).
At the time of donation, median donor age was
50.4 years (IQR 42.1–58.7). Eight hundred and six
donors (66.4%) were women and 408 (33.6%) were
men. Median BMI of all donors was 24.9 (IQR 22.7–
27.7). A total of 923 donors (76.0%) had normal blood
pressure and 95.2% did not have microalbuminuria
(ratio ≥3.3; median albumin-excretion ratio 0.7; IQR 0.4
–1.3).
At the time of donation, 271 donors (22.3%) were
diagnosed with hypertension (information on hyperten-
sion was missing in 20 patients). In 89 patients (32.6%),
the diagnosis of hypertension was made on the basis of
blood pressure measurement. All other patients were
classiﬁed on the basis of use of blood pressure-lowering
medications. Mean systole was 140.7 (range 100–205)
and mean diastole was 84.5 (range 60–113). table 1
reports a comparison with normotensive donors in
terms of albumin excretion rate, gender, age and BMI.
Occurrence of hypertension
Among initially normotensive donors, 398 (43.1%)
developed hypertension in the observation period and
provided 1302 data entries. Using the Framingham risk
calculator, the predicted risk for developing hyperten-
sion 1 year after donation was increased by 3.64 (95% CI
3.52 to 3.76; p<0.001). The estimated mean 1-year risk of
hypertension from the Framingham risk equation was
3.5%. The observed incidence of hypertension after
1 year among responders was 18.7% (151/807). In the
subset of the donor cohort that remained normotensive
Table 1 Comparison of albumin excretion rate, age,
gender and body mass index (BMI), between donors with
and without hypertension before donation
Donor characteristics before
kidney donation
p Value
Hypertensive
donors
(n=271)
Normotensive
donors
(n=943)
Albumin
excretion ratio
1.29 (SD 1.55) 1.22 (SD 3.02) 0.72
Age 58.1 (SD 9.0) 48.2 (SD 11.1) <0.001
Male gender 40.2% 31.9% 0.01
BMI 26.6 (SD 3.5) 24.8 (SD 3.6) <0.001
BMI, body mass index.
Figure 1 Rate of living kidney
donors with complete datasets at
each follow-up time point.
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1 year after donation and had non-missing values for
hypertension status 5 years after donation (n=451), the
risk was only modestly increased (1.19, 95% CI 1.10 to
1.29; p <0.001). Two hundred and one patients provided
data up to 10 years after donation. Occurrence of hyper-
tension is shown in ﬁgure 2. One hundred and six
remained normotensive. In the subgroup of donors
remaining normotensive 5 years after donation, the
cumulative incidence of developing hypertension in the
subsequent 5 years was 29/123 (23.6%). Results
remained essentially unchanged in sensitivity analyses.
table 2 shows mean systolic and diastolic blood pressure
values and ranges of hypertensive and normotensive
groups during follow-up. All hypertensive patients
remained hypertensive during the observation period.
The mean systolic (6.2 mm Hg (95% CI 4.1 to
8.4 mm Hg); p<0.001) and diastolic (5.0 mm Hg (3.4 to
6.6 mm Hg); p<0.001) blood pressure values of normo-
tensive donors predonation, who developed hyperten-
sion at 1-year follow-up, were slightly, albeit signiﬁcantly,
higher than the predonation values of those patients
who were normotensive at the 1-year follow-up, when
correcting for differences in age, male gender and BMI.
Occurrence of microalbuminuria
In all donors, the albumin excretion ratio increased
from 1.2±2.7 to 1.9±10.7 mg albumin/mmol creatinine
and the occurrence of microalbuminuria increased from
4.8% to 10.4% (ﬁgure 3). Twenty of 57 donors with
microalbuminuria were hypertensive (35.1%). Ten years
after nephrectomy, the rate of microalbuminuria
(>3.3 mg albumin/mmol creatinine) was signiﬁcantly
higher in the group of 271 initially hypertensive donors
as compared to normotensive donors (16.6% vs 6.0%,
p=0.03) (ﬁgure 4). Before donation, albumin excretion
was dependent on donor age but not on the presence of
hypertension (table 1). However, after nephrectomy,
multivariate random intercept models corrected for
repeated measures per donor showed that the effect of
Table 2 Mean systolic and diastolic blood pressure and ranges of hypertensive and normotensive groups, during follow-up
Normotensive variable
Hypertensive
Number Mean Minimum Maximum Number Mean Minimum Maximum
Before donation
Mean systole 923 120.7 89 140 271 140.7 100 205
Mean diastole 923 74.9 46 90 271 84.5 60 113
Number 260
1 year
Mean systole 555 121.0 86 140 252 140.9 88 220
Mean diastole 555 77.1 50 90 252 87.3 60 116
Number 229
3 years
Mean systole 408 122.3 90 140 198 142.9 109 187
Mean diastole 408 78.4 59 90 198 86.4 60 110
Number 194
5 years
Mean systole 272 121.9 85 140 179 141.0 100 190
Mean diastole 272 78.0 56 90 179 85.3 60 115
Number 161
7 years
Mean systole 177 123.3 95 140 142 140.1 100 189
Mean diastole 177 78.2 53 90 142 84.3 61 109
Number 128
10 years
Mean systole 86 122.5 83 140 93 141.2 107 210
Mean diastole 86 77.1 59 90 93 84.0 60 111
Number 74
Number of hypertensive patients on ACE inhibitor or AT1 receptor antagonist treatment (italics).
Figure 2 Number of donors at risk of hypertension among
201 providing 10 years of follow-up.
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age was lost and hypertension became the main driver
for increased albumin excretion (OR 1.19; 95% CI 0.13
to 2.25; p=0.03).
DISCUSSION
Our results show that kidney donation triplicates the
short-term risk among donors of developing hyperten-
sion and that after nephrectomy hypertension becomes
the main risk factor for microalbuminuria.
In earlier studies, hypertension after living kidney
donation was reported in 17–33% of donors.11–16
However, in the past, living kidney donation was not
regarded as a risk factor for hypertension as the inci-
dence of hypertension was similar to the age-matched
general population.17–25 These studies were limited by
their retrospective design, small donor cohorts, high rate
of donors lost to follow-up and use of the general popula-
tion as a control group.5 26 Also, a prospective study by
Ramesh Prasad et al27 on 51 consenting donors who
derived from a pool of 129 eligible donors, showed that
the predonation 24 h ambulatory blood pressure dipping
proﬁle (nocturnal blood pressure dipping) of normoten-
sive living kidney donors was not correlated with renal
function and cardiovascular risk status at the 1-year
follow-up after donation. Only recently, publications
taking an opposite view have become available. In 2014,
Mjoen et al28 published a paper estimating the all-cause
and the cardiovascular mortality and risk for end-stage
renal disease in kidney donors. Compared to a selected
population of non-donors who would have qualiﬁed for
to donate, the kidney donors showed an increased long-
term risks for kidney failure and mortality. Very recently,
results from the chronic renal impairment in
Birmingham donor study showed that the unilateral
nephrectomy in healthy subjects led to an increase in left
ventricular mass that correlated with the reduction in the
glomerular ﬁltration rate (GFR) within 1 year.29
The classiﬁcation of living kidney donors as being nor-
motensive or hypertensive is not as easy as primarily
expected. Normal blood pressure values do not allow a
donor to be classiﬁed as being normotensive when no
information is available on the use of antihypertensive
drugs on the day of blood pressure measurement. On
the contrary, hypertensive blood pressure readings
without conﬁrmation by 24 h blood pressure recording
may reﬂect white coat hypertension.30 31 In our study, all
new diagnoses of hypertension had to be veriﬁed by
24 h ambulatory blood pressure recording. Blood pres-
sure values in the normal range were only accepted as
‘normal’ if a list of drugs taken the same day was
reported to SOL-DHR. Only follow-up examinations
with complete data sets were analysed. In 2006,
Figure 4 Percentage of living kidney donors with
microalbuminuria (>3.3 mg albumin/mmol creatinine) over a
10-year follow-up period and stratified for hypertensives (red
bars) and normotensives (blue bars).
Figure 3 Rates of hypertension
in living kidney donors over a
10-year follow-up period and
microalbuminuria (>3.3 mg
albumin/mmol creatinine) in the
entire donor group, stratified for
hypertensives (red bars) and
normotensives (blue bars).
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Boudville et al3 concluded in their meta-analysis that
there was on average a 5 mm Hg increase in blood pres-
sure postnephrectomy but that they were unable to eval-
uate for any differences in risk of hypertension because
of heterogeneity in the data and weaknesses in the
underlying studies.
Strengths of the present study are the prospective
design, the large donor group, a high follow-up rate and
complete data sets, allowing a robust classiﬁcation of
hypertensive outcomes. In contrast to the follow-up of
organ recipients, follow-up of donors is cumbersome as
donors frequently live far from the transplant centres
and regard themselves as healthy without the need for
regular medical check-ups. Therefore, donors are
usually not prepared to travel long distances or cover the
expenses for their follow-up examinations. The key
factor for the high follow-up rate in this prospectively
designed long-term follow-up study was the Swiss trans-
plant law requiring a central donor registry and coverage
of medical expenses for donors’ biennial follow-up
examination by the kidney recipients’ compulsory
health insurance. At regular intervals, SOL-DHR pro-
vided donors with a questionnaire and medical follow-up
form to be ﬁlled out by the donor’s preferred local
family physician, with all medical expenses covered by
the recipients’ health insurance. Donors not returning
their follow-up forms were contacted by SOL-DHR,
using kidney recipients’ information, to obtain donor
contact details; if abroad, donors were contacted
through the worldwide network of Swiss embassies.
Hence, we regard the rate of 74% complete follow-up
examinations as the very best that can be achieved
under ideal circumstances. The 2704 completed
follow-up data sets allow for robust statistical analyses.
Missing information on donors’ smoking habits and
the family history of hypertension is a weakness of this
study. We tried to deal with it by imputing the missing
data. In the case of smoking, we based our assumptions
on the most recent epidemiological data on smoking
available in Switzerland.9 In view of the fact that donors
represent a healthy subgroup of the general public, we
believe that this is a conservative assumption and think
that the comparison is justiﬁable. Using lower rates for
smoking would have increased the excess of risk among
kidney donors. For positive family history, we assumed
that 25% had both parents with hypertension. This
assumption was based on a recently performed nation-
wide survey in Switzerland on salt intake.10 Again, it can
be argued that this is a conservative assumption given
the over-representation of healthy subjects in our cohort
resulting in a potential underestimation of the risk of
developing hypertension after donation. However, we
cannot deny that the lack of data on two risk parameters
that are used in the Framingham equation remains a
problem. All we could do was to assess to what extend
our assumptions affected the overall results. We were
reassured that the results only varied minimally when
repeating the analyses. Moreover, we cannot fully rule
out that our deﬁnition of hypertension, taking use of
antihypertensive medication as a part of the deﬁnition,
led to an overstated number of hypertensive cases,
because some normotensive patients might have
received ACE inhibitors or AT1 receptor antagonists
against microalbuminuria or β-blockers against anxiety.
Finally, even if a follow-up rate of 76% is very high, we
cannot fully exclude selection bias.
Hypertension is a common disease in the general
population, while kidney donors are a preselected heal-
thier subgroup. Hence, even a tripling of the risk of
hypertension, as shown in the present study, remained
unnoticed when the subgroup of healthy donors was
compared to the general population.17 23 32–35 Ideally,
donors after nephrectomy should be compared to a
population of accepted donors not able to donate owing
to recipient reasons or those refusing nephrectomy but
still being followed long term, to accurately reﬂect the
speciﬁc risk proﬁle of donors, including a high propor-
tion of women (66%) or normal BMI. Under the
assumption that the model is correct, the Framingham
risk equation allowed making the control population
similar for all relevant risk factors of hypertension. On
the contrary, the Framingham risk score was not speciﬁ-
cally validated for Switzerland and also does not take
into account that many donors are ﬁrst-degree relatives
to someone with a kidney ailment or possibly cardiovas-
cular disease.36 However, owing to the large group of
donors with complete follow-up data sets collected pro-
spectively by SOL-DHR during 17 years, it was possible
to compensate for differences in the risk proﬁle allowing
a robust analyses of nephrectomy as an independent risk
factor for hypertension.
Unilateral nephrectomy deprives the group of healthy
donors of their initial health advantage and puts them
at a threefold higher risk for developing hypertension.
Those participants remaining with normal blood pres-
sure 1 year after donation return to a risk similar to that
of the healthy Framingham population.
The second goal of this study was to assess the role
of nephrectomy as an independent risk factor for
microalbuminuria. Previous studies on small donor
groups reported an increase in microalbuminuria,
which was believed to be due to hyperﬁltration of the
remaining glomeruli after nephrectomy.17 23 32–35
Indeed, in the present donor cohort, GFR as estimated
by the Modiﬁcation of Diet in Renal Disease formula37
shows, despite removing half of the kidney mass, not
the theoretically expected fall to 50% of its initial
value but, instead, a reduction to approximately 70%,
indicating hyperﬁltration of the remaining glomeruli.
Over the 10-year follow-up period with 2704 serum
creatinine measurements after nephrectomy, GFR
remained stable with no sign of normal physiological
loss of GFR due to ageing or hyperﬁltration.38 In addi-
tion we could now identify hypertension as an impor-
tant driver for the development of microalbuminuria
after nephrectomy.
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Another relevant ﬁnding was obtained by analysing
the risk factors for microalbuminuria in donors before
and after nephrectomy. Before nephrectomy, variability
in albumin excretion was related to donor age but not
the presence of hypertension. However, after unilateral
nephrectomy, hypertension became the dominant factor
for albumin excretion, whereas donor age had no effect.
The possible underlying mechanisms explaining this
phenomenon remain unclear and warrant additional
(patho-)physiological investigations.
In summary, kidney donation increases the risk
among donors for developing hypertension and sensi-
tises the remaining kidney to hypertensive glomerular
damage as expressed by increased albumin excretion.
Whether such increased risk of developing hyperten-
sion and/or microalbuminuria translates into renal dys-
function, other morbidities or mortality, postdonation,
remains to be seen. However, both risks must be
addressed by offering donors life-long follow-up and
providing continued monitoring of blood pressure and
urinary albumin excretion. As hypertension becomes
the main risk factor for microalbuminuria, adequate
therapy with nephroprotective antihypertensive drugs
(ACE inhibitors or angiotensin receptor antagonists)
should be initiated as soon as kidney donors are diag-
nosed with hypertension. Transplant centres have to be
aware of their responsibility to organise long-term
follow-up schemes for living kidney donors to guarantee
their optimal medical long-term management.
Follow-up should be coordinated by the transplant
centre or a central registry, but performed by the
family physician in the donor’s neighbourhood, to
ensure life-long medical support.
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